Reimbursement Recommendations
Key Messages
- CADTH recommends that Jakavi should be reimbursed by public drug plans for the treatment of chronic graft-versus-host disease (cGvHD) if certain conditions are met.
- Jakavi should only be covered to treat patients aged 12 years and older who did not show an adequate response to corticosteroids or other systemic treatments.
- Jakavi should only be reimbursed if prescribed by specialists who have experience in the diagnosis and management of patients with cGvHD, and the cost of Jakavi is reduced.
